stoxline Quote Chart Rank Option Currency Glossary
Beam Therapeutics Inc. (BEAM)
23.9  -0.41 (-1.69%)    04-19 16:00
Open: 24.19
High: 24.94
Volume: 4,505,331
Pre. Close: 24.31
Low: 23.65
Market Cap: 1,952(M)
Technical analysis
2024-04-19 5:08:01 PM
Short term     
Mid term     
Targets 6-month :  37.07 1-year :  42.92
Resists First :  31.74 Second :  36.75
Pivot price 27.49
Supports First :  23.64 Second :  19.67
MAs MA(5) :  24.78 MA(20) :  28.99
MA(100) :  29.96 MA(250) :  28.6
MACD MACD :  -2.6 Signal :  -2.1
%K %D K(14,3) :  2.3 D(3) :  4
RSI RSI(14): 25.1
52-week High :  49.5 Low :  16.95
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ BEAM ] has closed above bottom band by 13.5%. Bollinger Bands are 17.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25 - 25.12 25.12 - 25.22
Low: 23.32 - 23.48 23.48 - 23.61
Close: 23.67 - 23.92 23.92 - 24.12
Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Headline News

Sun, 21 Apr 2024
International Assets Investment Management LLC Invests $1.85 Million in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Sun, 21 Apr 2024
International Assets Investment Management LLC Purchases New Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Fri, 19 Apr 2024
First Week of June 21st Options Trading For Beam Therapeutics - Nasdaq

Fri, 19 Apr 2024
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Fri, 19 Apr 2024
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of “Hold” from Analysts - Defense World

Wed, 17 Apr 2024
Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Down 6.1% in March - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 82 (M)
Held by Insiders 7.333e+007 (%)
Held by Institutions 1.8 (%)
Shares Short 13,110 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.5647e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -35.1 %
Operating Margin 42 %
Return on Assets (ttm) -7.9 %
Return on Equity (ttm) -15.5 %
Qtrly Rev. Growth 1 %
Gross Profit (p.s.) 270.05
Sales Per Share 2.13395e+008
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -149 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 1.3
Price to Book value 0
Price to Sales 0
Price to Cash Flow 3.39
Stock Dividends
Dividend 0
Forward Dividend 1.345e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android